ArticleCureus2025
Negative Pressure Wound Therapy With Saline Instillation Improves Early Healing in Purulent Soft-Tissue Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Negative pressure wound therapy (NPWT) is widely used in the treatment of purulent-inflammatory soft tissue diseases, while negative pressure wound therapy with instillation (NPWT-i) has recently emerged as a promising approach to enhance wound healing. Methods We conducted a prospective, single-center randomized study, including 29 patients with purulent-inflammatory soft tissue infections of the trunk and extremities treated between December 2024 and June 2025. Patients were randomized to conventional NPWT (Group I, n=17) or NPWT-i with normal saline (Group II, n=12) after accounting for exclusions during follow-up. All patients underwent standardized surgical debridement protocols, and outcomes were assessed by planimetric wound analysis, serum C-reactive protein (CRP) measurement, number of repeated surgical debridements, and length of hospital stay. Results By day 7 after initial surgical debridement, patients in the NPWT-i group demonstrated significantly greater granulation tissue formation (70.5 ± 4.6% vs. 48.7 ± 4.1%), reduced fibrin coverage (17.2 ± 1.4% vs. 28.1 ± 5.2%), and smaller areas of necrosis (12.3 ± 3.1% vs. 23.6 ± 2.8%) compared to the NPWT group (all p < 0.05). CRP levels decreased more rapidly with NPWT-i (49.4 ± 29.1 mg/L vs. 96.3 ± 14.2 mg/L, p < 0.05). Patients in the NPWT-i group required fewer repeat debridements (3.1 ± 0.7 vs. 5.4 ± 1.2, p < 0.05) and had a shorter mean hospital stay (32.5 ± 4.2 vs. 41.7 ± 6.1 days, p < 0.05). Conclusion NPWT-i accelerates wound healing, reduces inflammation, decreases the number of repeated surgical interventions, and shortens hospitalization compared with standard NPWT. This justifies NPWT-i consideration as an advanced therapeutic option, particularly for the management of extensive purulent wounds where efficient and early wound-bed preparation is critical. Further large-scale, multicenter trials are warranted to confirm these preliminary findings, evaluate long-term outcomes, and establish standardized instillation protocols.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.